Cancer treatment and prognosis
OwnerAnders Strom, Jan-Ake Gustafssoninventors
Life of this patent
Estimating the term…
Abstract
This invention relates to methods of cancer treatment and prognosis and in particular to such methods involving the HES-1 protein.
Claims50
Use of HES-1 in the preparation of a medicament for the treatment of cancer.
Use of an inhibitor of ER activity in the preparation of an medicament for the reduction of cancer cell proliferation.
Use according to any preceding claim wherein the HES-1 gene is upregulated.
A method of reducing the proliferation of cancer cells in vitro comprising increasing the level of HES-1 in those cells.
A method of enchancing the effect of HES-1 on the reduction of cancer cell proliferation in vitro by expression of an engineered HES-1 which exhibits improved characteristics compared to native (wild type) HES-1.
A method according to any one of clams 9 to 16 wherein the cancer cells are selected from breast, colon, prostate and lung cancer cells.
A method of monitoring cell proliferation in a subject comprising monitoring the expression of PCNA or Ki67 in a sample from the subject.
A method of monitoring the effectiveness and/or progress of cancer therapy in cancer cells in vitro comprising establishing the level of HES-1 in those cells wherein a lower level of HES-1 is indicative of an increase in cancer cell proliferation.
A method of screening compounds for use in cancer therapy comprising determining the effect of those compounds on the effect of HES-1 on cell proliferation aid selecting compounds which enhance the effect of HES-1 on cell proliferation.
Use of an HES-1 nucleotide sequence or part thereof, in the preparation of a medicament for gene therapy of cancer.
A pharmaceutical preparation comprising HES-1 protein or corresponding nucleotide, either native or synthetic or in any pharmacologically effective variation thereof together with a pharmaceutically acceptable carrier.
A pharmaceutical preparation comprising an inhibitor to the histone deacetylase regulated by HES-1.
A method of reducing the proliferation of cancer cells comprising increasing the levels of HES-1 in those cells.
A method of enhancing the effect of HES-1 on the reduction of cancer cell proliferation by expression of an engineered HES-1 which exhibits improved characteristics compared to native (wild type) HES-1.
A method of monitoring the effectiveness and/or progress of cancer therapy in cancer cells comprising establishing the level of HES-1 in those cells wherein a lower level of HES-1 is indicative of an increase in cancer cell proliferation.
A method of gene therapy comprising supplying to cells a HES-1 nucleotide sequence or part thereof.
Dependencies are inferred from the claim text.